search
Novo Nordisk
Trends
- 1Eli Lilly CEO Pins Growth Hopes On Retatrutide▼Eli Lilly CEO Bets On Weight-Loss Medicine Retatrutide As Next Growth Driver, Says Firm’s Future Has ‘Never Been Brighter’
Eli Lilly's chief executive said the company's future has 'never been brighter' as it positions retatrutide, its experimental weight-loss and diabetes drug, as the next major growth driver. The statement follows strong investor interest in Lilly's obesity pipeline, which already includes the blockbuster tirzepatide. Retatrutide is in late-stage trials and is viewed as a potential rival to next-generation obesity treatments. Markets are watching closely as competition in the weight-loss drug market intensifies with Novo Nordisk and others.
- 2Weight-loss jab maker's Vogue World sponsorship draws criticism●‘It’s problematic’: concern as weight-loss jab maker sponsors Vogue World event
Novo Nordisk, maker of the weight-loss injection Wegovy, is sponsoring Vogue's World event, prompting concern from health commentators who call the tie-up between a diet drug manufacturer and a leading fashion magazine problematic. Critics argue it glamorises medical weight loss at a publication long associated with narrow beauty standards, raising questions about commercial influence on body image messaging.